CardioFlow approves major merger, reshapes board, rebrands stock

MicroPort CardioFlow Medtech Corporation’s extraordinary general meeting on December 15, 2025, saw shareholders approve the merger agreement with MicroPort Cardiac Rhythm Management Limited. The resolution, which also grants directors a mandate to issue 3,953,847,407 new ordinary shares at HK$1.35 each to the target company’s shareholder, passed with 99.994232% of votes in favor.

Concurrently, the company announced significant board changes effective December 15, 2025. Mr. Zhao Liang and Ms. Yan Luying resigned as executive directors, while Mr. Zhang Junjie stepped down as a non-executive director. Dr. Brian Chang has been appointed as a non-executive director and co-chairman of the board, Mr. Philippe Wanstok as an executive director and deputy president, and Mr. Deng Aoyi as a non-executive director.

Effective December 22, 2025, the company's stock short name for trading on the Stock Exchange will change from "CARDIOFLOW-B" to "MP CARDIOFLOW-B" in English and from "心通醫療-B" to "微創心通-B" in Chinese, better reflecting the controlling relationship with MicroPort Scientific Corporation. The stock code remains 2160.